Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs
Abstract Background Dirofilaria immitis is a filarial parasite of dogs that can cause serious or fatal cardiopulmonary disease. Three studies were conducted to evaluate the efficacy and safety of monthly treatment with moxidectin in a chewable tablet product in combination with sarolaner and pyrante...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | Parasites & Vectors |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13071-019-3702-6 |
id |
doaj-fd4087c37c8d4a178fcb8f5675531a46 |
---|---|
record_format |
Article |
spelling |
doaj-fd4087c37c8d4a178fcb8f5675531a462020-11-25T03:36:01ZengBMCParasites & Vectors1756-33052019-09-0112111210.1186/s13071-019-3702-6Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogsKristina Kryda0Robert H. Six1Kelly F. Walsh2Susan J. Holzmer3Sara Chapin4Sean P. Mahabir5Melanie Myers6Tammy Inskeep7Jady Rugg8Blair Cundiff9Aleah Pullins10Michael Ulrich11John W. McCall12Tom L. McTier13Steven J. Maeder14Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Cheri-Hill Kennel and Supply Inc.TRS Labs Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Veterinary Medicine Research and Development, Zoetis, Inc.Abstract Background Dirofilaria immitis is a filarial parasite of dogs that can cause serious or fatal cardiopulmonary disease. Three studies were conducted to evaluate the efficacy and safety of monthly treatment with moxidectin in a chewable tablet product in combination with sarolaner and pyrantel to prevent heartworm disease in dogs after experimental challenge and in a clinical field study in the USA. Methods In two laboratory studies, dogs (8 per group) that had been inoculated 30 days prior with 50 third-stage D. immitis larvae were randomized to treatment on Day 0 with placebo or combination product, at the minimum dose of 24 µg/kg moxidectin, 2 mg/kg sarolaner and 5 mg/kg pyrantel (as pamoate salt). Study 2 also included groups treated with tablets containing moxidectin-alone (24 µg/kg) or sarolaner-alone (2 mg/kg). Efficacy was evaluated ~ 5 months after inoculation by adult heartworm counts at necropsy. In the field study, 410 dogs ≥ 8 weeks-old from 23 USA veterinary clinics were treated for 11 months with either combination product at 24–48 µg/kg moxidectin, 2–4 mg/kg sarolaner and 5–10 mg/kg pyrantel (n = 272) or Heartgard® Plus (ivermectin/pyrantel) at the label recommended dose rate (n = 138). Efficacy was evaluated on Day 330 using antigen and microfilaria testing to assess adult heartworm infection. Results In the laboratory studies, there were no heartworms recovered from any dog treated with the combination product or moxidectin alone and all dogs treated with placebo or sarolaner-alone were infected with 20–44 adult heartworms. In the field study, all dogs treated with the combination product tested negative for heartworm infection on Day 330, whereas two dogs treated with Heartgard® Plus tested positive. The Heartgard® Plus-treated dogs that tested heartworm positive were from the lower Mississippi River Valley region, where heartworm resistance has been confirmed to occur. The combination product was well tolerated in all studies. Conclusions In laboratory studies, no heartworms were recovered from dogs treated with a single dose of the novel combination product containing moxidectin, sarolaner and pyrantel. Additionally, in the field study no dog tested positive for adult heartworm infection when dosed with the combination product monthly for 11 months, while two dogs treated with Heartgard® Plus tested positive.http://link.springer.com/article/10.1186/s13071-019-3702-6Dirofilaria immitisHeartwormPreventionMacrocyclic LactoneSarolanerMoxidectin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kristina Kryda Robert H. Six Kelly F. Walsh Susan J. Holzmer Sara Chapin Sean P. Mahabir Melanie Myers Tammy Inskeep Jady Rugg Blair Cundiff Aleah Pullins Michael Ulrich John W. McCall Tom L. McTier Steven J. Maeder |
spellingShingle |
Kristina Kryda Robert H. Six Kelly F. Walsh Susan J. Holzmer Sara Chapin Sean P. Mahabir Melanie Myers Tammy Inskeep Jady Rugg Blair Cundiff Aleah Pullins Michael Ulrich John W. McCall Tom L. McTier Steven J. Maeder Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs Parasites & Vectors Dirofilaria immitis Heartworm Prevention Macrocyclic Lactone Sarolaner Moxidectin |
author_facet |
Kristina Kryda Robert H. Six Kelly F. Walsh Susan J. Holzmer Sara Chapin Sean P. Mahabir Melanie Myers Tammy Inskeep Jady Rugg Blair Cundiff Aleah Pullins Michael Ulrich John W. McCall Tom L. McTier Steven J. Maeder |
author_sort |
Kristina Kryda |
title |
Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs |
title_short |
Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs |
title_full |
Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs |
title_fullStr |
Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs |
title_full_unstemmed |
Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs |
title_sort |
laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (dirofilaria immitis) in dogs |
publisher |
BMC |
series |
Parasites & Vectors |
issn |
1756-3305 |
publishDate |
2019-09-01 |
description |
Abstract Background Dirofilaria immitis is a filarial parasite of dogs that can cause serious or fatal cardiopulmonary disease. Three studies were conducted to evaluate the efficacy and safety of monthly treatment with moxidectin in a chewable tablet product in combination with sarolaner and pyrantel to prevent heartworm disease in dogs after experimental challenge and in a clinical field study in the USA. Methods In two laboratory studies, dogs (8 per group) that had been inoculated 30 days prior with 50 third-stage D. immitis larvae were randomized to treatment on Day 0 with placebo or combination product, at the minimum dose of 24 µg/kg moxidectin, 2 mg/kg sarolaner and 5 mg/kg pyrantel (as pamoate salt). Study 2 also included groups treated with tablets containing moxidectin-alone (24 µg/kg) or sarolaner-alone (2 mg/kg). Efficacy was evaluated ~ 5 months after inoculation by adult heartworm counts at necropsy. In the field study, 410 dogs ≥ 8 weeks-old from 23 USA veterinary clinics were treated for 11 months with either combination product at 24–48 µg/kg moxidectin, 2–4 mg/kg sarolaner and 5–10 mg/kg pyrantel (n = 272) or Heartgard® Plus (ivermectin/pyrantel) at the label recommended dose rate (n = 138). Efficacy was evaluated on Day 330 using antigen and microfilaria testing to assess adult heartworm infection. Results In the laboratory studies, there were no heartworms recovered from any dog treated with the combination product or moxidectin alone and all dogs treated with placebo or sarolaner-alone were infected with 20–44 adult heartworms. In the field study, all dogs treated with the combination product tested negative for heartworm infection on Day 330, whereas two dogs treated with Heartgard® Plus tested positive. The Heartgard® Plus-treated dogs that tested heartworm positive were from the lower Mississippi River Valley region, where heartworm resistance has been confirmed to occur. The combination product was well tolerated in all studies. Conclusions In laboratory studies, no heartworms were recovered from dogs treated with a single dose of the novel combination product containing moxidectin, sarolaner and pyrantel. Additionally, in the field study no dog tested positive for adult heartworm infection when dosed with the combination product monthly for 11 months, while two dogs treated with Heartgard® Plus tested positive. |
topic |
Dirofilaria immitis Heartworm Prevention Macrocyclic Lactone Sarolaner Moxidectin |
url |
http://link.springer.com/article/10.1186/s13071-019-3702-6 |
work_keys_str_mv |
AT kristinakryda laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT roberthsix laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT kellyfwalsh laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT susanjholzmer laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT sarachapin laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT seanpmahabir laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT melaniemyers laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT tammyinskeep laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT jadyrugg laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT blaircundiff laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT aleahpullins laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT michaelulrich laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT johnwmccall laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT tomlmctier laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs AT stevenjmaeder laboratoryandfieldstudiestoinvestigatetheefficacyofanovelorallyadministeredcombinationproductcontainingmoxidectinsarolanerandpyrantelforthepreventionofheartwormdiseasedirofilariaimmitisindogs |
_version_ |
1724551827032113152 |